Human FGF21 Protein (His Tag)

UNQ3115 / PRO10196

• 100ug (NPP1281) Please inquiry

Catalog Number	P10911-H07E
Organism Species	Human
Host	E. coli
Synonyms	UNQ3115 / PRO10196
Molecular Weight	The recombinant human FGF21 consisting of 188 amino acids and has a calculated molecular mass of 20.2 kDa. It migrates as an 23 kDa band in SDS-PAGE under reducing conditions as predicted.
predicted N	Met
SDS-PAGE
Purity	> 95 % as determined by SDS-PAGE
Protein Construction	A DNA sequence encoding the mature form of human FGF21 (NP_061986.1) (His 29-Ser 209) was expressed, with a polyhistide tag at the N-terminus.
Bio-activity
Research Area	Developmental Biology |Morphogenesis |Fibroblast Growth Factor (FGF) & Receptor |Fibroblast Growth Factor (FGF)
Formulation	Lyophilized from 50 mM Tris, 10 % glycerol, 0.05 % Brig 35, pH 8.0 1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background	Fibroblast growth factor 21 (FGF21) is a member of the fibroblast growth factor (FGF) family. FGF family members possess broad mitogenic and cell survival activities and are involved in a variety of biological processes including embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion. FGF-21 has a hydrophobic amino terminus, which is a typical signal sequence, and appears to be a secreted protein. The metabolic regulator fibroblast growth factor 21 (FGF21) has antidiabetic properties in animal models of diabetes and obesity. FGF21 is a novel adipokine associated with obesity-related metabolic complications in humans. The paradoxical increase of serum FGF21 in obese individuals, which may be explained by a compensatory response or resistance to FGF21, warrants further investigation. FGF-21, which we have identified as a novel metabolic factor, exhibits the therapeutic characteristics necessary for an effective treatment of diabetes.
Reference	Zhang X, et al. (2008) Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes. 57(5): 1246-53. Lundåsen T, et al. (2007) PPARalpha is a key regulator of hepatic FGF21. Biochem Biophys Res Commun. 360(2): 437-40. Kharitonenkov A, et al. (2005) FGF-21 as a novel metabolic regulator. J Clin Invest. 115(6): 1627-35.